Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IP2 is an investigational oral dietary supplement developed by Toscana Life Sciences, consisting of a combination of collagen peptides, methylsulfonylmethane (MSM), and ascorbic acid (vitamin C). The product is designed to enhance skin health and appearance by providing structural support, reducing inflammation, and promoting endogenous collagen synthesis. Collagen peptides serve as building blocks for the dermal extracellular matrix, while MSM acts as a sulfur donor and anti-inflammatory agent, potentially through the inhibition of NF-kappaB signaling. Ascorbic acid serves as an essential cofactor for prolyl and lysyl hydroxylase enzymes, which are critical for the post-translational modification and cross-linking of collagen fibers. Clinical evaluations have focused on parameters such as dermis density, wrinkle reduction, skin texture, and elasticity, with further studies planned to investigate its efficacy in reducing facial erythema and telangiectasia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on collagen + methylsulfonylmethane + ascorbic acid.